info@strategicmarketresearch.com
26, Broadway, Suite 934, New York , 10004
us US: +1-315-636-4233    uk UK: +44-162-237-0614     in IN: +91-826-083-6500
Home » Healthcare » Cancer Monoclonal Antibodies Market Size | Forecast 2030

Cancer Monoclonal Antibodies Market By Antibody Type (Murine Antibodies, Chimeric Antibodies, Humanized Antibodies, Others), By Medication Type (Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix), Pertuzumab (Perjeta), Others), By Application (Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, Others), By End-User (Hospitals and Clinics, Pharmacies, Research Laboratories, Others), By Geography, Size, Share, Growth, Global Industry Report, Industry Forecast, 2021-2030

Published On: Jul-2022   |   Base Year: 2021   |   No Of Pages: 135   |   Historical Data: 2015 - 2019   |   Formats: PDF   |   Report ID: 42337305

Industry Report and Statistics (Facts & Figures) - Demand & Sales by Antibody Type, Medication & Application

The global cancer monoclonal antibodies market will witness a robust CAGR of 8.54%, valued at $51.88 billion in 2021, expected to appreciate and reach $108.47 billion by 2030, confirms Strategic Market Research. The Monoclonal antibodies are the laboratory-made antibodies that are assigned to certain targets in the body of the Homo Sapiens. They act as antigens on the surface of the carcinogenic cells. There are a plethora of monoclonal antibodies & each antibody is prepared so that it binds to only one type of antigen. These antibodies are widely used for the treatment of a variety of diseases along with certain types of cancers. They carry the injected drugs or radioactive substances directly to the cancer cells. A research survey revealed that cancer treatment using radioactive substances is the world's most common form of cancer therapy. Nearly 50% of the patients suffering from cancer undergo radiation therapy & which contributes to approximately 40% of the curative treatment of cancer.

The combination of radioactive substances with chemotherapy drugs is called Conjugated Monoclonal Antibodies. These antibodies are also widely employed in cancer treatment. They are a sort of targeted cancer treatment that interacts with specific targets. Certain monoclonal antibodies are also used as immunotherapy because they help to build the immune system against cancer. According to GLOBOCAN 2020 figures, an estimated 19,292,789 people will be diagnosed with cancer in 2020. According to the cited source, cancer patients are expected to reach 30.2 million by 2040.

 

Cancer Monoclonal Antibodies Market Infographic 2020-2030

 

Key Industry Drivers - Increasing Cancer Prevalence, Increasing Demand for the Specificity of Monoclonal Antibodies to Target Cancer, and Increasing Focus on R&D in Cancer Serology.

  • Cancer is affecting an increasing number of individuals throughout the world. According to the World Health Organization's (WHO) February 2022 estimate, Cancer will claim the lives of around 10 million people globally in 2020. Prostate, lung, bowel, and female breast cancer are the four most frequent kinds of Cancer globally, accounting for 44 percent of all new cancer cases.

 

  • According to the paper "Monoclonal antibodies and Cancer Treatment: What to Know," released in November 2020, Cancer isn't the only condition treated with monoclonal antibodies. The coronavirus has also been discovered as an antibody target. By inhibiting infected cells from being proliferated, monoclonal antibodies assist in decreasing the duration of severe sickness. Due to the increased usage of monoclonal antibodies in COVID-19, the cancer monoclonal antibodies market analyzed was severely influenced.

 

  • Monoclonal antibodies market growth potential will be boosted by a strong focus on researching and developing naked monoclonal antibody therapies to provide highly targeted drug therapy for complicated and severe illnesses. Companies would profit greatly from government backing and regulatory permissions to build the monoclonal antibody business. For instance, According to Bristol Myers Squibb, in 2021, The European Commission (EC) authorized Bristol Myers Squibb's OPDIVO and Yervoy combination medication to treat hematologic malignancies in pleural mesothelioma patients. As a result, the product line's availability in the market will be extended.

 

Restraints - Huge Costs Associated with the Making of Monoclonal Antibodies

  • Due to the complicated production process, clinical studies, expensive biological and chemical components,  and mandatory safety, testing, effectiveness, and quality checks, the high costs associated with developing monoclonal antibodies using modern techniques operate as a key restraint for the market. Large-scale manufacturing of monoclonal antibodies involves numerous post-translational modifications that need advanced equipment, which is costly and disulfide bonds. Clinical effectiveness is often obtained by injecting huge doses of monoclonal antibodies into the system, necessitating the production of large quantities for each therapy, raising the cost. AJMC (American Journal of Managed Care) states that monoclonal antibody medicines for oncology and hematology cost roughly $100,000 more per year than those for other diseases. As a result, the market expansion will be limited by the huge development costs of these new approaches.

 

Opportunities - Increasing Consumption of Tobacco, Rise of Government Initiatives

  • According to the WHO (World Health Organization), in February 2022, tobacco smoking, a high body mass index, a low fruit and vegetable diet, alcohol consumption, and a lack of physical exercise account for around one-third of cancer fatalities. As a result, rising tobacco usage is predicted to increase cancer prevalence, boosting industry growth.

 

  • The rise of cancer cases worldwide has compelled governments worldwide to invest a hefty amount in laboratories to manufacture highly efficient monoclonal antibodies for cancer treatment. Moreover, the governments have also increased their approval rate for monoclonal antibodies, which can cater to a plethora of opportunities for the market in the years to come. SMR conducted a thorough research study revealing that the U.S. FDA approved more than 100 monoclonal antibodies for treating various cancers.

 

Global Cancer Monoclonal Antibodies Market Share 2020-2030

 

Cancer Monoclonal Antibodies Market Analysis Of Different Segments Covered in the Report

Based on the Medication Type

  • Bevacizumab (Avastin)

  • Rituximab (Mabthera)

  • Pertuzumab (Perjeta)

  • Panitumumab (Vectibix)

  • Cetuximab (Erbitux)

  • Trastuzumab (Herceptin)

  • Others

 

Based on End-User

  • Hospitals and Clinics

  • Pharmacies

  • Research Laboratories

  • Others

 

Based on Antibody Type

  • Murine Antibodies

  • Chimeric Antibodies

  • Humanized Antibodies

  • Others

 

Based on Application

  • Breast Cancer

  • Blood Cancer

  • Liver Cancer

  • Brain Cancer

  • Colorectal Cancer

  • Others

 

Regional Coverage Analysis

North America

  • The U.S.

  • Canada

  • Mexico

  • Rest of North America

 

Europe

  • France

  • Germany

  • U.K

  • Spain

  • Italy

  • Rest of Europe

 

Asia Pacific

  • India   

  • China

  • Japan

  • Australia

  • Rest of APAC

 

LAMEA

  • Brazil

  • South Africa

  • Saudi Arabia

  • Rest of LAMEA

 

Cancer Monoclonal Antibodies Market End-user 2020-2030

 

Segments Analysis & Insights

Based on Medication Type, Trastuzumab (Herceptin) held the largest cancer monoclonal antibodies market share in 2020. It's also the first-line therapy for HER2-positive metastatic stomach or gastro-oesophageal junction cancer. Because of the prolonged length of therapy in conjunction with Perjeta, the market has continued to expand. The increased global prevalence of Cancer will boost the segment's expansion. As asserted by World Health Organization (WHO), 2.3 million women were diagnosed and detected with breast cancer in 2020, with 685,000 deaths worldwide. Breast cancer has been diagnosed in 7.8 million women in the previous five years ending in 2020, making it the most common worldwide disease. As a result, the increasing frequency of rapidly spreading breast cancer will increase the demand for Herceptin monoclonal antibodies, leading to industry growth.

 

In the End-User segment, Hospitals held the maximum share due to a rise in the number of patients admitted to hospitals for various chronic illnesses. Patient preference has been influenced by the availability of modern medication therapy in institutions. Highly skilled professionals providing specialized treatments for diseases such as autoimmune diseases and cancer will drive the demand of the product in hospitals. On top of that, better reimbursement policies for high-cost therapies prevailing in hospitals will influence patient visits.

 

In the Regions segment, North America held the maximum share. Biotechnology and Pharmaceutical companies have a wealth of experience and understanding in cancer monoclonal antibodies. According to the American Cancer Society's 2022 projections, roughly 235,000 new lung cancer cases will be detected in the United States in 2022. According to the same source, around 79,000  instances of kidney cancer would be diagnosed in 2022, with 13,800 fatalities. The increased prevalence of cancer is predicted to increase demand for ablation devices, resulting in market expansion.  

 

Cancer Monoclonal Antibodies Market Report Coverage

Report Attribute

Details

Forecast Period

2021 - 2030

The market size value in 2021

USD 51.88 Billion

The revenue forecast in 2030

USD 108.47 Billion

Growth rate

CAGR of approximately 8.54%

The base year for estimation

2021

Unit

USD Billion, CAGR (2021 - 2030)

Segmentation

By Solutions, By Deployment, By Region

By Medication Type

Rituximab (Rituxan), Bevacizumab (Avastin), Cetuximab (Erbitux), Panitumumab (Vectibix), Trastuzumab (Herceptin), and Others

By End-User

Hospitals and Clinics, Research Laboratories, Others

By Region

Asia Pacific, North America, Europe, LAMEA

Country Scope

U.S., Canada, France, Germany, U.K., China, Japan, India, South Korea, Mexico, Brazil, U.A.E. etc.

Company Usability Profiles

Bristol Myers Squibb Company, Johnson & Johnson, Novartis AG, F. Hoffmann-La Roche AG, Genmab AS, Amgen Inc., GlaxoSmithKline PLC, Eli Lilly and Company, Seattle Genetics Inc., and Spectrum Pharmaceuticals Inc., among others, hold the substantial market share in the market studied.

 

Cancer Monoclonal Antibodies Market Competitive Landscape Analysis

The competitive landscape analysis entails information about the global competitors who are operating in the dynamic marketplace. The comparison is performed based on initiatives, company overview, investment in R&D, company financials, overall revenue generation, company strengths and weaknesses, global presence, SWOT Analysis, production capacity, PESTLE Analysis, production sites and facilities, potential, etc.

 

Cancer Monoclonal Antibodies Market region 2020-2030

 

Recent Developments

  • On July 2022, Next Cure announced the development of a highly effective Immunohistochemical assay for further laboratory investigations on monoclonal antibodies. This IHC (immunohistochemical) assay was manufactured with the combination of S15 Monoclonal Antibody that detects a unique & rare cytoplasmic domain of the respective protein.

 

  • On July 2022, Junshi Biosciences & Coherus announced that the FDA has successfully approved the resubmission of Toripalimab for the treatment of Nasopharyngeal Cancer. Toripalimab is an anti-PD 1 Monoclonal antibody developed to block the PD-1 interactions with its respective ligands.

 

  • On July 2022, AstraZeneca announced that it is planning to acquire TeneoTwo of worth USD 100 million. It is by far the largest deal made by a pharmaceutical company for developing a new type of targeted cancer therapy known as T Cell Engager. Moreover, it also declared that the phase 1 testing of a drug called TNB-486 is already in the process. If this drug achieves the desired level of efficiency milestone, then the TeneoTwo shareholders have the possibility to receive payments up to USD 1.16 Billion.

 

  • In the month of February 2022, FDA granted the approval for ciltacabtagene autoleucel (CARVYKTI, Janssen Biotech, Inc), which will be used to treat adult patients suffering from relapsed or with refractory multiple myeloma who have undergone four or more therapy procedures that includes an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and anti-CD38 monoclonal antibody.

 

  • In January 2021, In the EU, the antibody-drug combination trastuzumab deruxtecan acquired conditional approval for use as a single agent in patients who are adults with unresectable or metastatic HER2-positive breast cancer who have previously undergone two or more HER2-based regimens.

 

  • In September 2020, AbbVie and I-Mab formed a strategic agreement to develop and market lemzoparlimab (also known as TJC4), a monoclonal antibody medication used to treat a variety of malignancies.

 

  • In March 2020, Gilead Sciences, a biopharmaceutical business located in the United States, agreed to buy Forty Seven for $4.9 billion. With the inclusion of Forty Seven's exploratory lead product candidate, magrolimab, this purchase is expected to boost Gilead's immuno-oncology R&D portfolio. 

 

Frequently Asked Question About This Report

In the Regions segment, North America held the maximum share. Pharmaceutical and biotechnology companies have a wealth of experience and understanding in cancer monoclonal antibodies.

A total of 24 monoclonal antibodies (mAbs) targeting 16 distinct solid Tumor antigens have been authorised for the treatment of a growing variety of malignancies.

Cancer is treated with antibodies such as trastuzumab, pembrolizumab, and rituximab.

Monoclonal Antibodies (MABs) are a specific form of targeted pharmacological treatment. These medications are able to identify and locate certain proteins and kill cancer cells.

Therapeutic monoclonal antibodies have been gaining popularity year after year. Their very specific antigen targeting can give very effective medical therapy, and molecular-targeted medicine is permitting the overall development of the new generation of therapeutic medicines.

North America has the highest growth rate.

Amgen Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche AG, Genmab AS, GlaxoSmithKline PLC, Eli Lilly and Company, Novartis AG, Johnson & Johnson, Seattle Genetics Inc., and Spectrum Pharmaceuticals Inc. few among others, are the most promising players who are operating in the global market.

The global cancer monoclonal antibodies market size was $51.88 Billion in 2021. It is estimated to reach $108.47 Billion by 2030, representing a CAGR of 8.54% throughout the forecasted period of 2021-2030.

The global market size in 2021 was around USD 51.88 Billion and it is expected to expand at an 8.54% CAGR from 2020 to 2030. As a result, the Global market Forecast suggests reaching around USD 108.47 Billion by 2030.

Sources

https://www.who.int/news-room/fact-sheets/detail/cancer

https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-as-First-Line-Treatment-for-Patients-with/default.aspx

https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html

 

 

1.   Introduction

       1.1. Study Objective

       1.2. Market Definition        

       1.3. Study Scope

              1.3.1. Markets Covered

              1.3.2. Geographic Scope

              1.3.3. Years Considered

              1.3.4. Stakeholders

2.   Research Methodology

       2.1. Data Procurement

       2.2. Paid Database

              2.2.1. Secondary Data

                     2.2.1.1. Key Secondary sources

              2.2.2. Primary Data

                     2.2.2.1 Primary sources

                     2.2.2.2. Key industry insights

                     2.2.2.3. Primary interviews with experts

                     2.2.2.4. Key primary respondent list

       2.3. Market Size Estimation

       2.4. Bottom-Up and Top-Down Approaches

              2.4.1.     Bottom-Up Approach

                     2.4.1.1.         Approach for arriving at market size by bottom-up analysis

              2.4.2.     Top-Down Approach

                     2.4.2.1.         Approach for Capturing Market Size by Top-Down Analysis

       2.5. Market Breakdown and Data Triangulation

       2.6. Research Methodology

       2.7. Risk Assessment

3.  Executive Summary

       3.1 Cancer Monoclonal Antibodies Market: Post-Covid-19

              3.1.1      Actual Scenario

              3.1.2      Pessimistic Scenario

              3.1.3      Optimistic Scenario

              3.1.4      Market Summary

4. Industry Outlook

       4.1 Market Snapshot

       4.2 Cancer Monoclonal Antibodies Market

              4.2.1      market, 2021 – 2030 (USD Million)

       4.3 Regional Business Analysis

              4.3.1      market, by region, 2021 - 2030 (USD Million)

       4.4 By Medication Type Business Analysis

              4.4.1      market, By Medication Type, 2021 - 2030 (USD Million)

       4.5 By Application Business Analysis

              4.5.1      market, By Application, 2021 - 2030 (USD Million)

       4.6 End-User Business Analysis

              4.6.1      market, By End-User, 2021 - 2030 (USD Million)

       4.6 Antibody Type Business Analysis

              4.6.1      market, By Antibody Type, 2021 - 2030 (USD Million)

       4.7 Value Chain Analysis

       4.8 Market Variable Analysis

              4.8.1      Market Drivers Analysis

              4.8.2      Market Restraints Analysis

       4.9 Business Environment Analysis Tool

              4.9.1      market PEST analysis

              4.9.2      market Porter’s analysis

       4.10 Penetration & Growth Prospect Mapping

5. Market Dynamics

       5.1. Introduction

       5.2. Market Dynamics

              5.2.1.     Drivers

              5.2.2.     Restraints

              5.2.3.     Opportunities

              5.2.4.     Challenges

       5.3. Impact of Covid-19 On Market

       5.4. Value Chain Analysis

       5.5. Ecosystem

       5.6. Patent Analysis

       5.7. Trade Analysis

       5.8. Tariff Analysis

       5.9. Case Study Analysis

5.10.      Porter’s Five Forces Analysis

              5.10.1    Threat of New Entrants

              5.10.2    Threat of Substitutes

              5.10.3    Bargaining Power of Buyers

              5.10.4    Bargaining Power of Suppliers

              5.10.5    Degree of Competition

       5.11.              Antibody Type Analysis

              5.11.1.   Trends in Antibody Type (2014-2021)

              5.11.2.   Trends in Antibody Type (2021-2030)

       5.12.              Pricing Analysis

              5.12.1.   Average Price Trend Analysis (By Region, By Country)

6. Competitive & Vendor Landscape

       6.1. Company Market Share Analysis

       6.2. Manufacturers Manufacturing Sites, Area Served, Medication Type

       6.3. Market Competitive Situation and Trends

       6.4. Manufacturers Mergers & Acquisitions, Expansion Plans

7. Market: By Medication Type Segment Analysis

       7.1. Introduction

       7.2. Sales Volume & Revenue Analysis (2021-2030)

       7.3. Bevacizumab (Avastin)

              7.3.1. Bevacizumab (Avastin) market, 2021 - 2030 (USD Million)

       7.4. Rituximab (Rituxan)

               7.4.1. Rituximab (Rituxan) market, 2021 - 2030 (USD Million)

       7.5. Trastuzumab (Herceptin)

               7.5.1. Trastuzumab (Herceptin) market, 2021 - 2030 (USD Million)

       7.6. Cetuximab (Erbitux)

               7.6.1. Cetuximab (Erbitux) market, 2021 - 2030 (USD Million)

       7.7. Panitumumab (Vectibix)

               7.7.1. Panitumumab (Vectibix) market, 2021 - 2030 (USD Million)

       7.8. Others

               7.8.1. Others market, 2021 - 2030 (USD Million)

8. Market: By Application Segment Analysis

       8.1. Introduction

       8.2. Sales Volume & Revenue Analysis (2021-2030)

       8.3. Breast Cancer

              8.3.1.     Breast Cancer Market, 2021 - 2030 (USD Million)

       8.4. Blood Cancer

              8.4.1.     Labor-Management market, 2021 - 2030 (USD Million)

       8.5. Liver Cancer

              8.5.1.     Liver Cancer market, 2021 - 2030 (USD Million)

       8.6. Brain Cancer

              8.6.1.     Brain Cancer market, 2021 - 2030 (USD Million)

       8.7. Colorectal Cancer

              8.7.1.     Colorectal Cancer market, 2021 - 2030 (USD Million)

       8.8. Others

              8.8.1.     Others market, 2021 - 2030 (USD Million)

9. Market: By End-User Segment Analysis

       9.1. Introduction

       9.2. Sales Volume & Revenue Analysis (2021-2030)

       9.3. Cloud

              9.3.1.     Cloud market, 2021 - 2030 (USD Million)

       9.4. Pharmacies

              9.4.1.     Pharmacies market, 2021 - 2030 (USD Million)

       9.5. Research Laboratories

              9.5.1.     Research Laboratories market, 2021 - 2030 (USD Million)

       9.6. Others

              9.6.1.     Others market, 2021 - 2030 (USD Million)

10. Market: By Antibody Type Segment Analysis

       10.1. Introduction

       10.2. Sales Volume & Revenue Analysis (2021-2030)

       10.3. Murine Antibodies

              10.3.1.   Murine Antibodies market, 2021 - 2030 (USD Million)

       10.4. Chimeric Antibodies

              10.4.1.   Chimeric Antibodies market, 2021 - 2030 (USD Million)

       10.5. Humanized Antibodies

              10.5.1.   Humanized Antibodies Market, 2021 - 2030 (USD Million)

       10.6. Others

              10.6.1.   Others market, 2021 - 2030 (USD Million)

11. Market: Regional Outlook

       11.1 North America

              11.1.1.   North America market, By Medication Type, 2021 - 2030 (USD Million)

              11.1.2.   North America market, By Application, 2021 - 2030 (USD Million)

              11.1.3.   North America market, by Antibody Type, 2021 - 2030 (USD Million)

              11.1.4.   North America market, by Country, 2021 - 2030 (USD Million)

       11.1.4.1. U.S.

                     11.1.4.1.1.   U.S. market, By Medication Type, 2021 - 2030 (USD Million)

                     11.1.4.1.2.   U.S. market, By Application, 2021 - 2030 (USD Million)

                     11.1.4.1.3.   U.S. market, by Antibody Type, 2021 - 2030 (USD Million)

     11.1.4.2.  Canada

                     11.1.4.2.1.   Canada market, By Medication Type, 2021 - 2030 (USD Million)

                     11.1.4.2.2.   Canada market, By Application, 2021 - 2030 (USD Million)

                     11.1.4.2.3.   Canada market, by Antibody Type, 2021 - 2030 (USD Million)

11.2. Europe

              11.2.1.   Europe market, By Medication Type, 2021 - 2030 (USD Million)

              11.2.2.   Europe market, By Application, 2021 - 2030 (USD Million)

              11.2.3.   Europe market, by Antibody Type, 2021 - 2030 (USD Million)

              11.2.4.   Europe market, by country, 2021 - 2030 (USD Million)

    11.2.4.1    U.K.

                     11.2.4.1.1.   U.K. market, By Medication Type, 2021 - 2030 (USD Million)

                     11.2.4.1.2.   U.K. market, By Application, 2021 - 2030 (USD Million)

                     11.2.4.1.3.   U.K. market, by Antibody Type, 2021 - 2030 (USD Million)

   11.2.4.2.           Germany

                     11.2.4.2.1.   Germany market, By Medication Type, 2021 - 2030 (USD Million)

                     11.2.4.2.2.   Germany market, By Application, 2021 - 2030 (USD Million)

                     11.2.4.2.3.   Germany market, by Antibody Type, 2021 - 2030 (USD Million)

   11.2.4.3.           France

                     11.2.4.3.1.   France market, By Medication Type, 2021 - 2030 (USD Million)

                     11.2.4.3.2.   France market, By Application, 2021 - 2030 (USD Million)

                     11.2.4.3.3.   France market, by Antibody Type, 2021 - 2030 (USD Million)

    11.2.4.4.          Rest of Europe

                     11.2.4.4.1.   Rest of Europe market, By Medication Type, 2021 - 2030 (USD Million)

                     11.2.4.4.2.   Rest of Europe market, By Application, 2021 - 2030 (USD Million)

                     11.2.4.4.3.   Rest of Europe market, by Antibody Type, 2021 - 2030 (USD Million)

       11.3.              Asia Pacific

              11.3.1.   Asia Pacific market, By Medication Type, 2021 - 2030 (USD Million)

              11.3.2.   Asia Pacific market, By Application, 2021 - 2030 (USD Million)

              11.3.3.   Asia Pacific market, by Antibody Type, 2021 - 2030 (USD Million)

              11.3.4.   Asia Pacific market, by country, 2021 - 2030 (USD Million)

   11.3.4.1.           China

                     11.3.4.1.1.   China market, By Medication Type, 2021 - 2030 (USD Million)

                     11.3.4.1.2.   China market, By Application, 2021 - 2030 (USD Million)

                     11.3.4.1.3.   China market, by Antibody Type, 2021 - 2030 (USD Million)

   11.3.4.2.           India

                     11.3.4.2.1.   India market, By Medication Type, 2021 - 2030 (USD Million)

                     11.3.4.2.2.   India market, By Application, 2021 - 2030 (USD Million)

                     11.3.4.2.3.   India  market, by Antibody Type, 2021 - 2030 (USD Million)

   11.3.4.3.           Japan

                     11.3.4.3.1.   Japan market, By Medication Type, 2021 - 2030 (USD Million)

                     11.3.4.3.2.   Japan market, By Application, 2021 - 2030 (USD Million)

                     11.3.4.3.3.   Japan market, by Antibody Type, 2021 - 2030 (USD Million)

   11.3.4.4.           South Korea

                     11.3.4.4.1.   South Korea market, By Medication Type, 2021 - 2030 (USD Million)

                     11.3.4.4.2.   South Korea market, By Application, 2021 - 2030 (USD Million)

                     11.3.4.4.3.   South Korea market, by Antibody Type, 2021 - 2030 (USD Million)

11.3.4.5.              Rest of ASIA PACIFIC

                     11.3.4.5.1.   Rest of ASIA PACIFIC market, By Medication Type, 2021 - 2030 (USD Million)

                     11.3.4.5.2.   Rest of ASIA PACIFIC market, By Application, 2021 - 2030 (USD Million)

                     11.3.4.5.3.   Rest of ASIA PACIFIC market, by Antibody Type, 2021 - 2030 (USD Million)

       11.4.              Latin America

              11.4.1.   Latin America market, By Medication Type, 2021 - 2030 (USD Million)

              11.4.2.   Latin America market, By Application, 2021 - 2030 (USD Million)

              11.4.3.   Latin America market, by Antibody Type, 2021 - 2030 (USD Million)

              11.4.4.   Latin America market, by country, 2021 - 2030 (USD Million)

11.4.4.1.              Brazil

                     11.4.4.1.1.   Brazil market, By Medication Type, 2021 - 2030 (USD Million)

                     11.4.4.1.2.   Brazil market, By Application, 2021 - 2030 (USD Million)

                     11.4.4.1.3.   Brazil market, by Antibody Type, 2021 - 2030 (USD Million)

11.4.4.2.              Mexico

                     11.4.4.2.1.   Mexico market, By Medication Type, 2021 - 2030 (USD Million)

                     11.4.4.2.2.   Mexico market, By Application, 2021 - 2030 (USD Million)

                     11.4.4.2.3.   Mexico market, by Antibody Type, 2021 - 2030 (USD Million)

                     11.4.4.3.       Rest of Latin America

                     11.4.4.3.1.   Rest of the Latin America market, By Medication Type, 2021 - 2030 (USD Million)

                     11.4.4.3.2.   Rest of the Latin America market, By Application, 2021 - 2030 (USD Million)

                     11.4.4.3.3.   Rest of the Latin America market, by Antibody Type, 2021 - 2030 (USD Million)

       11.5.     MEA

              11.5.1.   MEA market, By Medication Type, 2021 - 2030 (USD Million)

              11.5.2.   MEA market, By Application, 2021 - 2030 (USD Million)

              11.5.3.   MEA market, by Antibody Type, 2021 - 2030 (USD Million)

              11.5.4.   MEA market, by region, 2021 - 2030 (USD Million)

 

12. Competitive Landscape

       12.1 AMGEN INC

              12.1.1.   Company overview

              12.1.2.   Financial performance

              12.1.3.   Medication Type Portfolio Analysis

              12.1.4.   Business Strategy & Recent Development

       12.2. Bristol Myers Squibb Company

              12.2.1.   Company overview

              12.2.2.   Financial performance

              12.2.3.   Medication Type Portfolio Analysis

              12.2.4.   Business Strategy & Recent Development

       12.3. Eli Lilly and Company

              12.3.1.   Company overview

              12.3.2.   Financial performance

              12.3.3.   Medication Type Portfolio Analysis

              12.3.4.   Business Strategy & Recent Development

       12.4. F. Hoffmann-La Roche AG

              12.4.1.   Company overview

              12.4.2.   Financial performance

              12.4.3.   Medication Type Portfolio Analysis

              12.4.4.   Business Strategy & Recent Development

       12.5. Genmab AS

              12.5.1.   Company overview

              12.5.2.   Financial performance

              12.5.3.   Medication Type Portfolio Analysis

              12.5.4.   Business Strategy & Recent Development

       12.6. GlaxoSmithKline PLC

              12.6.1.   Company overview

              12.6.2.   Financial performance

              12.6.3.   Medication Type Portfolio Analysis

              12.6.4.   Business Strategy & Recent Development

       12.7. JOHNSON & JOHNSON

              12.7.1.   Company overview

              12.7.2.   Financial performance

              12.7.3.   Medication Type Portfolio Analysis

              12.7.4.   Business Strategy & Recent Development

       12.8. NOVARTIS AG

              12.8.1.   Company overview

              12.8.2.   Financial performance

              12.8.3.   Medication Type Portfolio Analysis

              12.8.4.   Business Strategy & Recent Development

       12.9. Seattle Genetics Inc

              12.9.1.   Company overview

              12.9.2.   Financial performance

              12.9.3.   Medication Type Portfolio Analysis

              12.9.4.   Business Strategy & Recent Development

        12.10. Spectrum Pharmaceuticals Inc

              12.10.1.   Company overview

              12.10.2.   Financial performance

              12.10.3.   Medication Type Portfolio Analysis

              12.10.4.   Business Strategy & Recent Development

 

List of Tables (61 Tables)

TABLE 1.  MARKET, By Medication Type, 2021-2030 (USD Million)

TABLE 2.  MARKET FOR Bevacizumab (Avastin), BY REGION, 2021-2030 (USD Million)

TABLE 3.  MARKET FOR Rituximab (Rituxan), BY REGION, 2021-2030 (USD Million)

TABLE 4.  MARKET FOR Trastuzumab (Herceptin), BY REGION, 2021-2030 (USD Million)

TABLE 5.  MARKET FOR Cetuximab (Erbitux), BY REGION, 2021-2030 (USD Million)

TABLE 6.  MARKET FOR Panitumumab (Vectibix), BY REGION, 2021-2030 (USD Million)

TABLE 7.  MARKET FOR Others, BY REGION, 2021-2030 (USD Million)

TABLE 8. MARKET, By Application, 2021-2030 (USD Million)

TABLE 9. MARKET FOR Breast Cancer, BY REGION, 2021-2030 (USD Million)

TABLE 10. MARKET FOR Blood Cancer, BY REGION, 2021-2030 (USD Million)

TABLE 11. MARKET FOR Liver Cancer, BY REGION, 2021-2030 (USD Million)

TABLE 12. MARKET FOR Brain Cancer, BY REGION, 2021-2030 (USD Million)

TABLE 13. MARKET FOR Colorectal Cancer, BY REGION, 2021-2030 (USD Million)

TABLE 14. MARKET FOR Others, BY REGION, 2021-2030 (USD Million)

TABLE 15. MARKET, BY ANTIBODY TYPE, 2021-2030 (USD Million)

TABLE 16. MARKET FOR Murine Antibodies, BY REGION, 2021-2030 (USD Million)

TABLE 17. MARKET FOR Chimeric Antibodies, BY REGION, 2021-2030 (USD Million)

TABLE 18. MARKET FOR Humanized Antibodies, BY REGION, 2021-2030 (USD Million)

TABLE 19. MARKET FOR Others, BY REGION, 2021-2030 (USD Million)

TABLE 20. MARKET, By End-User, 2021-2030 (USD Million)

TABLE 21. MARKET FOR Hospitals and Clinics, BY REGION, 2021-2030 (USD Million)

TABLE 22. MARKET FOR Pharmacies, BY REGION, 2021-2030 (USD Million)

TABLE 23. MARKET FOR Research Laboratories, BY REGION, 2021-2030 (USD Million)

TABLE 24. MARKET FOR Others, BY REGION, 2021-2030 (USD Million)

TABLE 25. MARKET, BY REGION, 2021-2030 (USD Million)

TABLE 26. NORTH AMERICA MARKET, BY COUNTRY, 2021-2030 (USD Million)

TABLE 27. NORTH AMERICA MARKET, By Medication Type, 2021-2030 (USD Million)

TABLE 28. NORTH AMERICA MARKET, By Application, 2021-2030 (USD Million)

TABLE 29. NORTH AMERICA MARKET, BY ANTIBODY TYPE, 2021-2030 (USD Million)

TABLE 30. EUROPE MARKET, BY COUNTRY, 2021-2030 (USD Million)

TABLE 31. EUROPE MARKET, By Medication Type, 2021-2030 (USD Million)

TABLE 32. EUROPE MARKET, By Application, 2021-2030 (USD Million)

TABLE 33. EUROPE MARKET, BY ANTIBODY TYPE, 2021-2030 (USD Million)

TABLE 34. ASIA-PACIFIC MARKET, BY COUNTRY, 2021-2030 (USD Million)

TABLE 35. ASIA-PACIFIC MARKET, By Medication Type, 2021-2030 (USD Million)

TABLE 36. ASIA-PACIFIC MARKET, By Application, 2021-2030 (USD Million)

TABLE 37. ASIA-PACIFIC MARKET, BY ANTIBODY TYPE, 2021-2030 (USD Million)

TABLE 38. LAMEA MARKET, BY COUNTRY, 2021-2030 (USD Million)

TABLE 39. LAMEA MARKET, By Medication Type, 2021-2030 (USD Million)

TABLE 40. LAMEA MARKET, By End-User, 2021-2030 (USD Million)

TABLE 41. LAMEA MARKET, BY ANTIBODY TYPE, 2021-2030 (USD Million)

TABLE 42. AMGEN INC: COMPANY SNAPSHOT

TABLE 43. AMGEN INC: OPERATING SEGMENTS

TABLE 44. Bristol Myers Squibb Company: COMPANY SNAPSHOT

TABLE 45. Bristol Myers Squibb Company: OPERATING SEGMENTS

TABLE 46. Eli Lilly and Company: COMPANY SNAPSHOT

TABLE 47. Eli Lilly and Company: OPERATING SEGMENTS

TABLE 48. F. Hoffmann-La Roche AG: COMPANY SNAPSHOT

TABLE 49. F. Hoffmann-La Roche AG: OPERATING SEGMENTS

TABLE 50. Genmab AS: COMPANY SNAPSHOT

TABLE 51. Genmab AS: OPERATING SEGMENTS

TABLE 52. GlaxoSmithKline PLC: COMPANY SNAPSHOT

TABLE 53. GlaxoSmithKline PLC: OPERATING SEGMENTS

TABLE 54. JOHNSON & JOHNSON: COMPANY SNAPSHOT

TABLE 55. JOHNSON & JOHNSON: OPERATING SEGMENTS

TABLE 56. NOVARTIS AG: COMPANY SNAPSHOT

TABLE 57. NOVARTIS AG: OPERATING SEGMENTS

TABLE 58. Seattle Genetics Inc: COMPANY SNAPSHOT

TABLE 59. Seattle Genetics Inc: OPERATING SEGMENTS

TABLE 60. Spectrum Pharmaceuticals Inc: COMPANY SNAPSHOT

TABLE 61. Spectrum Pharmaceuticals Inc: OPERATING SEGMENTS

 

List of Figures (22 Figures)

Figure 1 Market: Research Methodology Steps

Figure 2 Research Design

Figure 3 Breakdown of Primaries: Market

Figure 4 Research Methodology: Hypothesis Building

Figure 5 Market: Medication Type-Based Estimation

Figure 6 Top 10 Companies with Highest No. Of Patent in Last 9 Years

Figure 7 No. Of Patents Granted Per Year, 2019–2021

Figure 8 Import Data for Cancer Monoclonal Antibodies, By Country, 2016–2021 (USD Thousand)

Figure 9 Export Data for Cancer Monoclonal Antibodies, By Country, 2016–2021 (USD Thousand)

Figure 10 Data Triangulation Methodology

Figure 11 Market, By Application, 2019 vs. 2025 (USD Million)

Figure 12 Market Share, By Antibody Type, 2019 vs. 2025 (USD Million)

Figure 13 Market Share, By Medication Type, 2019 vs. 2025 (USD Million)

Figure 14 Market Share, By End-User, 2019 vs. 2025 (USD Million)

Figure 15 Geographical Snapshot of the Market

Figure 16 Trastuzumab (Herceptin) to Witness Higher CAGR in the Market for Medication Type Segment During the Forecast Period.

Figure 17 Hospitals and Clinics to Witness Higher CAGR in Market for End-User Segment during Forecast Period.

Figure 18 North America Accounted for the Largest Share of the Market, By Regional Basis, in 2019

Figure 19 Market: Drivers, Restraints, Opportunities, and Challenges

Figure 20 North America: Market Snapshot

Figure 21 Asia Pacific: Market Snapshot

Figure 22 Vendor Dive: Evaluation Overview